44 results on '"Siegmund, B."'
Search Results
2. Glutensensitive Enteropathie, Zöliakie
- Author
-
Schumann, M., primary and Siegmund, B., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Autoren
- Author
-
Andrié, R.P., primary, Angenendt, J., additional, Aubin, H., additional, Baldus, S., additional, Balzer, J., additional, Baltzer, J., additional, Behr, J., additional, Benz, Marcus, additional, Berger, M., additional, Blank, N., additional, Blind, E., additional, Buchfelder, M., additional, Burk, A., additional, Detter, C., additional, Diel, R., additional, Diener, H.-C., additional, Domschke, W., additional, Doppler, K., additional, Ellinger, J., additional, Epple, H.-J., additional, Erbel, R., additional, Fichtner-Feigl, S., additional, Fischereder, M., additional, Forsting, M., additional, Friedrich, M., additional, Frommberger, U., additional, Frye, B.C., additional, Goebel, F.-D., additional, Grabitz, K., additional, Groeneveld, A., additional, Gundling, F., additional, Gutt, C.N., additional, Haidl, G., additional, Hartmann, U., additional, Hausteiner-Wiehle, C., additional, Herpertz-Dahlmann, B., additional, Heuß, D., additional, Heußner, P., additional, Hiller, E., additional, Hohenfellner, U., additional, Honegger, J., additional, Hornung, T., additional, Jansen, F., additional, Jelinek, T., additional, Jordan, B., additional, Keck, C., additional, Kelm, M., additional, Kilian, A., additional, Kleindienst, A., additional, Kölbl, H., additional, Kreis, M.E., additional, Kroener-Herwig, B., additional, Külz, A.K., additional, Lammert, F., additional, Lichtenberg, A., additional, Limmroth, V., additional, Lindner, K., additional, Loddenkemper, R., additional, Lorenz, H.-M., additional, Lügering, N., additional, Mallmann, P., additional, Max, R., additional, Merle, U., additional, Mellert, F., additional, Michels, G., additional, Müller, R.-U., additional, Müller, S.C., additional, Müller-Lissner, S., additional, Müller-Quernheim, J., additional, Neuhof, C., additional, Parhofer, K.G., additional, Petri, E., additional, Pfeiffer, T., additional, Pilatz, Adrian, additional, Pizarro, C., additional, Probst, C., additional, Rascher, W., additional, Raue, F., additional, Reindl, C., additional, Riedner, C., additional, Riemann, D., additional, Röckelein, V., additional, Sandmann, W., additional, Sauerbruch, T., additional, Schahab, N., additional, Schaper, A., additional, Schepp, W., additional, Schliep, S., additional, Schnürch, H.-G., additional, Schölmerich, J., additional, Schönermarck, Ulf, additional, Schopohl, J., additional, Schuchert, A., additional, Schulze-Koops, H., additional, Schupp, J., additional, Segerer, S.E., additional, Senninger, N., additional, Seybold, U., additional, Siegmund, B., additional, Skowasch, D., additional, Sommer, C., additional, Stahl, M., additional, Stallmach, A., additional, Sticherling, M., additional, Stremmel, W., additional, Sure, U., additional, Tacke, F., additional, Vloet, T., additional, Voderholzer, U., additional, von Kodolitsch, Y., additional, Wagenlehner, F., additional, Wahlers, T., additional, Weber, L.T., additional, Weidner, W., additional, Weis-Müller, B.T., additional, Werner, N., additional, Wintergerst, U., additional, Wolf, Gunter, additional, Ziegler, D., additional, Zierz, S., additional, and Zimmermann, Th., additional
- Published
- 2019
- Full Text
- View/download PDF
4. Chronische Diarrhö
- Author
-
Tröger, H., primary and Siegmund, B., additional
- Published
- 2018
- Full Text
- View/download PDF
5. Dünndarmstörungen als Teilaspekt systemischer Erkrankungen
- Author
-
Daum, S., primary and Siegmund, B., additional
- Published
- 2018
- Full Text
- View/download PDF
6. Malassimilationssyndrom
- Author
-
Siegmund, B., primary and Schumann, M., additional
- Published
- 2018
- Full Text
- View/download PDF
7. Autoren
- Author
-
Albers, P., primary, Andrié, R.P., additional, Angenendt, J., additional, Appenrodt, B., additional, Arkudas, A., additional, Aubin, H., additional, Autschbach, R., additional, Baldus, S., additional, Balzer, J., additional, Baltzer, J., additional, Behr, J., additional, Behrens, A., additional, Benz, Marcus, additional, Berger, M., additional, Berr, F., additional, Bischoff, S.C., additional, Böhm, A., additional, Böhm, M., additional, Bokemeyer, D., additional, Borowitzka, F., additional, Brüwer, M., additional, Buchfelder, M., additional, Burk, A., additional, Caca, K., additional, Daum, S., additional, Detter, C., additional, Diener, H.-C., additional, Domschke, W., additional, Doppler, K., additional, Elger, C.E., additional, Ell, C., additional, Ellinger, J., additional, Epple, H.-J., additional, Esser, B., additional, Ewen, Sebastian, additional, Fibbe, C., additional, Fichtner-Feigl, S., additional, Fiegel, P., additional, Fischbach, W., additional, Fischereder, M., additional, Fölsch, U.R., additional, Forsting, M., additional, Frey, N., additional, Freys, S.M., additional, Friedrich, M., additional, Frieling, T., additional, Frommberger, U., additional, Frühmorgen, P., additional, Geidel, S., additional, Germer, C.-T., additional, Goebel, F.-D., additional, Goetzenich, A., additional, Grabitz, K., additional, Greetfeld, M., additional, Groeneveld, A., additional, Groha, P.K., additional, Gundling, F., additional, Gutt, C.N., additional, Haak, T., additional, Hartmann, U., additional, Hauner, H., additional, Hausteiner-Wiehle, C., additional, Henningsen, P., additional, Herpertz-Dahlmann, B., additional, Heuß, D., additional, Heußner, P., additional, Hoffmann, J., additional, Hohenfellner, U., additional, Horch, R.E., additional, Hüll, M., additional, John, S., additional, Jordan, B., additional, Jurowich, C., additional, Käberich, A., additional, Katus, H., additional, Keck, C., additional, Kelm, M., additional, Kiehne, K., additional, Kilian, Adrienne, additional, Kindermann, I., additional, Kleindienst, A., additional, Klingel, K., additional, von Kodolitsch, Y., additional, Kölbl, H., additional, Koletzko, S., additional, Kollmar, O., additional, Konstantinidis, S., additional, Kramer, H.J., additional, Kreis, M.E., additional, Kroener-Herwig, B., additional, Kurschat, C., additional, Lammert, F., additional, Lamprecht, G., additional, Langosch, J.M., additional, Layer, P., additional, Leifeld, L., additional, Lichtenberg, A., additional, Lindner, K., additional, Link, A., additional, Lügering, N., additional, Lusch, Achim, additional, Marth, T., additional, Merle, U., additional, Mellert, F., additional, Meyer-Marcotty, M., additional, Michels, G., additional, Middeke, J.M., additional, Möddel, G., additional, Mössner, J., additional, Müller, A., additional, Müller, J.L., additional, Müller, R.-U., additional, Müller, S.C., additional, Müller-Lissner, S., additional, Müller-Werdan, U., additional, Neubrand, M., additional, Neuhof, C., additional, Parhofer, K.G., additional, Petri, E., additional, Pfeiffer, T., additional, Pilatz, Adrian, additional, Pizarro, C., additional, Pohle, T., additional, Polykandriotis, E., additional, Probst, C., additional, Rascher, W., additional, Rauch, B., additional, Reuss-Borst, M., additional, Riedner, C., additional, Rietschel, E., additional, Röckelein, V., additional, Rüster, Ch., additional, Ruß, M., additional, Sailer, M., additional, Sandmann, W., additional, Sauerbruch, T., additional, Schaaf, B., additional, Schaefer, C.A., additional, Schahab, N., additional, Schaper, A., additional, Schetelig, J., additional, Schmitz, M., additional, Schnürch, H.-G., additional, Schölmerich, J., additional, Schönermarck, Ulf, additional, Schrickel, J.W., additional, Schuchert, A., additional, Schunkert, H., additional, Segerer, S.E., additional, Senninger, N., additional, Seybold, U., additional, Siegmund, B., additional, Skowasch, D., additional, Sommer, C., additional, Spengler, U., additional, Stahl, M., additional, Stallmach, A., additional, Stolpmann, G., additional, Stremmel, W., additional, Sure, U., additional, Tacke, F., additional, te Wildt, B.T., additional, Trinkler, P., additional, Tröger, H., additional, Unnewehr, M., additional, Vloet, T., additional, Voderholzer, U., additional, Vogt, P.M., additional, von Scheidt, W., additional, Wagenlehner, F., additional, Wahlers, T., additional, Weber, L.T., additional, Wehrmann, T., additional, Weis-Müller, B.T., additional, Werdan, K., additional, Wintergerst, U., additional, Wittwer, T., additional, Wolf, Gunter, additional, Wölfling, K., additional, Wolkersdörfer, G., additional, Ziegler, D., additional, and Zierz, S., additional
- Published
- 2018
- Full Text
- View/download PDF
8. Glutensensitive Enteropathie, Zöliakie
- Author
-
Schumann, M., primary and Siegmund, B., additional
- Published
- 2018
- Full Text
- View/download PDF
9. Akute infektiöse Enteritiden bei Erwachsenen
- Author
-
Epple, H.-J., primary and Siegmund, B., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Biogenesis of aroma compounds
- Author
-
Siegmund, B., primary
- Published
- 2015
- Full Text
- View/download PDF
11. Chronische Diarrhö
- Author
-
Tröger, H., primary and Siegmund, B., additional
- Published
- 2015
- Full Text
- View/download PDF
12. List of contributors
- Author
-
Balagiannis, D.P., primary, Beauchamp, J., additional, Behrens, M., additional, Buettner, A., additional, Cerny, C., additional, Elmore, J.S., additional, Festring, D., additional, Fisk, I.D., additional, Guichard, E., additional, Hofmann, T., additional, Jansen, F.J.H.M., additional, Methven, L., additional, Meyerhof, W., additional, Monteleone, E., additional, Mottram, D.S., additional, Nakamoto, T., additional, Parker, J.K., additional, Prescott, J., additional, Ridgway, K., additional, Siegmund, B., additional, Suess, B., additional, Van der Schaft, P., additional, Wagenstaller, M., additional, and Wyszynski, B., additional
- Published
- 2015
- Full Text
- View/download PDF
13. Dünndarmstörungen als Teilaspekt systemischer Erkrankungen
- Author
-
Daum, S., primary and Siegmund, B., additional
- Published
- 2015
- Full Text
- View/download PDF
14. Glutensensitive Enteropathie
- Author
-
Siegmund, B., primary
- Published
- 2010
- Full Text
- View/download PDF
15. Malassimilationssyndrom
- Author
-
Siegmund, B., primary
- Published
- 2010
- Full Text
- View/download PDF
16. Determination of sulfur and nitrogen compounds during the processing of dry fermented sausages and their relation to amino acid generation
- Author
-
Corral, Sara, Leitner, E., Siegmund, B., Flores Llovera, Mónica, Corral, Sara, Leitner, E., Siegmund, B., and Flores Llovera, Mónica
- Abstract
© 2015 Elsevier Ltd. All rights reserved. The identification of odor-active sulfur and nitrogen compounds formed during the processing of dry fermented sausages was the objective of this study. In order to elucidate their possible origin, free amino acids (FAAs) were also determined. The volatile compounds present in the dry sausages were extracted using solvent assisted flavor evaporation (SAFE) and monitored by one and two-dimensional gas chromatography with different detectors: mass spectrometry (MS), nitrogen phosphorous (NPD), flame photometric (FPD) detectors, as well as gas chromatography-olfactometry. A total of seventeen sulfur and nitrogen compounds were identified and quantified. Among them, 2-acetyl-1-pyrroline was the most potent odor active compound, followed by methional, ethylpyrazine and 2,3-dihydrothiophene characterized by toasted, cooked potato, and nutty notes. The degradation of FAAs, generated during processing, was related to the production of aroma compounds, such as methionine forming methional and benzothiazole while ornithine was the precursor compound for 2-acetyl-1-pyrroline and glycine for ethylpyrazine.
- Published
- 2016
17. Treatment strategies for Spondyloarthritis: Implementation of precision medicine - Or "one size fits all" concept?
- Author
-
Proft F, Duran TI, Ghoreschi K, Pleyer U, Siegmund B, and Poddubnyy D
- Abstract
Spondyloarthritis (SpA) is a term to describe a group of chronic inflammatory rheumatic diseases, which have common pathophysiological, genetic, and clinical features. Under the umbrella term SpA, two main groups are subsumed: axial SpA (radiographic axSpA and non-radiographic axSpA) and peripheral SpA (with the leading representative being psoriatic arthritis (PsA) but also arthritis associated with inflammatory bowel disease (IBD), reactive arthritis, and undifferentiated pSpA). The key clinical symptom in axSpA is chronic back pain, typically with inflammatory characteristics, which starts in early adulthood, while the leading clinical manifestations of peripheral SpA (pSpA) are arthritis, enthesitis, and/or dactylitis. Furthermore, extra-musculoskeletal manifestations (EMMs) (acute anterior uveitis, psoriasis, and IBD) can accompany axial or peripheral symptoms. All these factors need to be taken into account when making treatment decisions in SpA patients. Despite the major advances in the treatment landscape over the past two decades with the introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) and most recently targeted synthetic DMARDs (tsDMARDs), a relevant proportion of patients still does not achieve the desired state of remission (=absence of disease activity). With this implementation of new treatment modalities, clinicians now have more choices to make in the treatment algorithms. However, despite generalized treatment recommendations, all factors need to be carefully considered when deciding on the optimal treatment strategy for an individual patient in clinical practice, aiming at an important first step towards personalized treatment strategies in SpA. In this narrative review, we focus on the efficacy of approved and emerging treatment options in axSpA and PsA as the main representative of pSpA and discuss their selective effect on the different manifestations associated with SpA to provide guidance on drivers of treatment decisions in specific situations., Competing Interests: Declaration of competing interest TID: has nothing to disclose. FP: received grants and personal fees from Novartis, Eli Lilly, and UCB and personal fees from AbbVie, AMGEN, BMS, Celgene, Galapagos, Janssen, Hexal, Medscape, MSD, Pfizer and Roche outside the presented work. KG: received grants or contracts from Bristol Myers Squibb; received consulting fees from Abbvie, Lilly, Almirall, Janssen, Boehringer Ingelheim, Pfizer, Bristol Myers Squibb, and UCB; received payment /honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Abbvie Allergan Alimera Bayer Novartis Pfizer Roche Santen Thea; received support for attending meetings and/or travel from Abbvie, Almirall, BMS, and Lilly. UP: received grants or contracts from EU, BMBF; received consulting fees from Affibody, Alcon, Allergan, Janssen, Novartis, Panoptes, Pfizer, Roche, Thea, Lilly, Pfizer, Santen. Holds patents EP 19732357.9, PCT/EP2019/066419, PCT/J/2020–570,837.BS: received grants or contracts from Pfizer; received consulting fees from Abbvie, Abivax, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Endpoint Health, Falk Pharma, Galapagos, Gilead, Janssen, Landos, Lilly, Pfizer, and Takeda; received payment /honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Abbvie, BMS, CED Service GmbH, Eli Lilly, Falk Pharma, Ferring, Galapagos, Janssen, Lilly, Pfizer, and Takeda.DP: received consulting fees from AbbVie, Biocad, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, MSD, Moonlake, Novartis, Pfizer, Samsung Bioepis and UCB; received payment /honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, MSD, Medscape, Novartis, Peervoice, Pfizer and UCB., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus.
- Author
-
Olivera PA, Dignass A, Dubinsky MC, Peretto G, Kotze PG, Dotan I, Kobayashi T, Ghosh S, Magro F, Faria-Neto JR, Siegmund B, Danese S, and Peyrin-Biroulet L
- Subjects
- Humans, Risk Assessment, Sphingosine 1 Phosphate Receptor Modulators therapeutic use, Sphingosine 1 Phosphate Receptor Modulators adverse effects, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases complications, Cardiovascular Diseases prevention & control, Delphi Technique, Consensus, Janus Kinase Inhibitors therapeutic use, Janus Kinase Inhibitors adverse effects
- Abstract
Janus kinase (JAK) inhibitors and sphingosine 1 phosphate (S1P) receptor modulators are small molecule drugs (SMDs) approved for IBD treatment. Their use in clinical practice might be limited due to cardiovascular concerns. We aimed to provide guidance on risk assessment, monitoring, and management strategies, aiming to minimize potential cardiovascular risks of SMDs and to facilitate an adequate shared decision-making. A systematic literature search was conducted, and proposed statements were prepared. A virtual consensus meeting was held, in which eleven IBD physicians and two cardiovascular specialists from ten countries attended. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75 % of participants voting as 'agree' with each statement. Consensus was reached for eighteen statements. Available evidence does not show a higher risk of cardiovascular events with JAK inhibitors in the overall IBD population, although it might be increased in patients with an unfavorable cardiovascular profile. S1P receptor modulators may be associated with a risk of bradycardia, atrioventricular blocks, and hypertension. Cardiovascular risk stratification should be done before initiation of SMDs. Although the risk of cardiovascular events in patients with IBD on SMDs appears to be low overall, caution should still be taken in certain scenarios., Competing Interests: Conflict of Interest PAO declares no conflict of interest. AD reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis, and end point committees from Abivax, AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb/Celgene, Dr Falk Foundation, Galapagos, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, Janssen, Materia Prima, MedToday, MSD, Pfizer, Streamed-Up, Takeda, Tillotts, and Vifor Pharma; payment for manuscript preparation from Falk Foundation, Takeda, Thieme, and UniMed Verlag. MCD has received consulting fees from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Pfizer Inc, Prometheus Laboratories, Takeda, and UCB. GP declares no conflict of interest. PGK: speaking and consultancy honorarium from Abbvie, Janssen, Pfizer and Takeda; Scientific grants from Pfizer and Takeda. ID has served as a speaker, consultant, or advisory board member for Takeda, Janssen, AbbVie, Pfizer, Eli-Lilly, Ferring, Roche/Genentech, Cambridge Healthcare, Celgene/BMS, Falk Pharma, Ierative Scopes, Rafa Laboratories, Neopharm, Arena, Gilead, Galapagos, Celltrion, Sublimity, Sandoz, Abbott, and Athos Therapeutics. TK has served as a speaker, a consultant or an advisory board member for AbbVie, Alfresa Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen, JIMRO, Kyorin Pharmaceutical, Kissei, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Sekisui Medical, Takeda Pharmaceutical, Zeria Pharmaceutical, and received research funding from AbbVie, Alfresa Pharma, EA Pharma, Gilead, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Sekisui Medical, Takeda Pharmaceutical, Zeria Pharmaceutical. SG reports research grants from GSK, Abbvie; Drug Monitoring Committee from Janssen, Steering Committees from BMS, Receptos, Janssen, Abbvie, Gilead, Galapagos; Lecture fees from Takeda, Pfizer, Janssen, Abbvie, BMS, Galapagos, Gilead, Celltrion and consulting fees from Abbvie, Janssen, Takeda, Pfizer, Galapagos, Celltrion, Ferring. FM has served as a speaker and received honoraria from Abbvie, Arena, Biogen, Bristol-Myers Squibb, Falk, Ferring, Hospira, Janssen, Laboratórios Vitoria, Pfizer, Lilly, Merck Sharp & Dohme, Sandoz, Takeda, UCB, and Vifor. JRFN declares no conflict of interest. BS has consulted for AbbVie, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Endpoint Health, Falk Pharma, Galapagos, Janssen, Landos, Lilly, Pfizer, Prometheus, and Takeda; has received speaker fees from AbbVie, CED Service GmbH, Falk Pharma, Ferring, Janssen, Novartis, Pfizer, and Takeda, and has received funding from Pfizer. SD has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson & Johnson, Millenium Takeda, MSD, NikkisoEurope GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma, and Vifor. LPB reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Al-lergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from AbbVie, MSD, Takeda, Fresenius Kabi; and has stock options in CTMA., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Ileal mucus viscoelastic properties differ in Crohn's disease.
- Author
-
Kramer C, Rulff H, Ziegler JF, Mönch PW, Alzain N, Addante A, Kuppe A, Timm S, Schrade P, Bischoff P, Glauben R, Dürr J, Ochs M, Mall MA, Gradzielski M, and Siegmund B
- Subjects
- Humans, Male, Female, Adult, Viscosity, Middle Aged, Elasticity, Intestinal Mucosa pathology, Intestinal Mucosa metabolism, Pilot Projects, Young Adult, Crohn Disease, Ileum pathology, Mucus metabolism, Rheology
- Abstract
Crohn's disease (CD) is an inflammatory bowel disease that can affect any part of the gastrointestinal tract, frequently involving the terminal ileum. While colonic mucus alterations in CD patients have been described, terminal ileal mucus and its mechanobiological properties have been neglected. Our study is the first of its kind to decipher the viscoelastic and network properties of ileal mucus. With that aim, oscillatory rheological shear measurements based on an airway mucus protocol that was thoroughly validated for ileal mucus were performed. Our pilot study analyzed terminal ileum mucus from controls (n = 14) and CD patients (n = 14). Mucus network structure was visualized by scanning electron microscopy. Interestingly, a statistically significant increase in viscoelasticity as well as a decrease in mesh size was observed in ileal mucus from CD patients compared to controls. Furthermore, rheological data were analyzed in relation to study participants' clinical characteristics, revealing a noteworthy trend between non-smokers and smokers. In conclusion, this study provides the first data on the viscoelastic properties and structure of human ileal mucus in the healthy state and Crohn's disease, demonstrating significant alterations between groups and highlighting the need for further research on mucus and its effect on the underlying epithelial barrier., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
- Author
-
Liokatis P, Liokati I, Obermeier K, Smolka W, Ersan F, Dewenter I, Otto S, Philipp P, Siegmund B, Walz C, Braunschweig T, Klauschen F, and Mock A
- Subjects
- Humans, Prognosis, Lymph Nodes pathology, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell mortality, Oropharyngeal Neoplasms pathology, Oropharyngeal Neoplasms mortality, Mouth Neoplasms pathology, Mouth Neoplasms mortality, Neoplasm Micrometastasis pathology, Lymphatic Metastasis
- Abstract
Background: An estimated 20% of patients with oral and oropharyngeal squamous cell carcinoma (OOSCC) have micrometastases (Mi) or isolated tumor cells (ITC) in the cervical lymph nodes that evade detection by standard histological evaluation of lymph node sections. Lymph node Mi and ITC could be one reason for regional recurrence after neck dissection. The aim of this study was to review the existing data regarding the impact of Mi on the survival of patients with OOSCC., Methods: PubMed and the Cochrane Library were searched for articles reporting the impact of Mi and ITC on patient survival. Two authors independently assessed the methodological quality of retrieved studies using the Downs and Black index. Data were also extracted on study type, number of included patients, mode of histological analysis, statistical analysis, and prognostic impact., Results: Sixteen articles with a total of 2064 patients were included in the review. Among the 16 included studies, eight revealed a statistically significant impact of Mi on at least one endpoint in the Kaplan-Meier and/or multivariate analysis. Three studies regarded Mi as Ma, while five studies found no impact of Mi on survival. Only one study demonstrated an impact of ITC on patient's prognosis in the univariate but not in the multivariate analysis., Conclusion: The majority of cases included in the review were patients with oral cancer. The findings provide low-certainty evidence that Mi negatively impacts survival. Data on ITC were scarcer, so no conclusions can be drawn about their effect on survival. The lower threshold to discriminate between Mi and ITC should be defined for OOSCC since the existing thresholds are based on data from different tumors. The histological, immunohistological, and anatomical characteristics of Mi and ITC in OOSCC as well as the effect of radiotherapy on Mi should be further investigated separately for oral and oropharyngeal carcinomas., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.
- Author
-
Solitano V, Facheris P, Petersen M, D'Amico F, Ortoncelli M, Aletaha D, Olivera PA, Bieber T, Ramiro S, Ghosh S, D'Agostino MA, Siegmund B, Chary-Valckenaere I, Hart A, Dagna L, Magro F, Felten R, Kotze PG, Jairath V, Costanzo A, Kristensen LE, Biroulet LP, and Danese S
- Subjects
- Humans, Autoimmune Diseases drug therapy, Inflammation drug therapy, Inflammation immunology, Pharmacovigilance, Practice Guidelines as Topic, Risk Assessment, Janus Kinase Inhibitors therapeutic use, Janus Kinase Inhibitors adverse effects
- Abstract
Background and Aims: The Pharmacovigilance Risk Assessment Committee (PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases (IMID). Use of these medications in individuals aged 65 and older, those at high cardiovascular risk, active or former long-term smokers, and those with increased cancer risk should be considered only if no alternatives exist. Caution is advised when administering JAKi to patients at risk of venous thromboembolism. We aim to implement recommendations from regulatory guidelines based on areas of uncertainty identified., Methods: A two-round modified Research and Development/University of California Los Angeles appropriateness methodology study was conducted. A panel of 21 gastroenterologists, dermatologists and rheumatologists used a 9-point Likert scale to rate the appropriateness of administering a JAKi for each proposed clinical scenario. Scores for appropriateness were categorized as appropriate, uncertain, or inappropriate. Two rounds were performed, each with online surveys and a virtual meeting to enable discussion and rating of each best practice., Results: Round 1 involved participants rating JAKi appropriateness and suggesting descriptors to reduce uncertainty. Survey results were discussed in a virtual meeting, identifying areas of disagreement. In round 2, participants rated their agreement with descriptors from round 1, and the level of uncertainty and disagreement reduced. Age flexibility is recommended in the absence of other risk factors. Active counseling on modifiable risks (e.g., overweight, mild hyperlipidemia and hypertension) and smoking cessation is advised. Uncertainty persists regarding cancer risk due to various factors., Conclusions: We outlined regulatory guidance without a personalized evaluation of the patient's risk profile might lead to uncertainty and become an arid technicality. Therefore, we identified gaps and implemented PRAC recommendations to help health professionals in clinical practice., Competing Interests: Declaration of Competing Interest Virginia Solitano and Magnus Petersen declare no conflict of interest. Paola Facheris has served as consultant for Eli Lilly. Ferdinando D'Amico has served as a speaker for Sandoz, Janssen, Galapagos, and Omega Pharma. He has also served as advisory board member for Abbvie, Ferring, Galapagos, and Nestlè. Michela Ortoncelli has declared no conflicts of interest. Daniel Aletaha received grants from AbbVie, Amgen, Galapagos, Eli Lilly and Sanofi, and honoraria (speaker's bureau, consultancy) from AbbVie, Amgen, Galapagos, Eli Lilly, Janssen, Merck, Novartis, Pfizer and Sandoz and is a member of the ARD Editorial Board. Pablo A. Olivera received consulting fees from Abbvie, Takeda, and Janssen and lecture fees from Takeda and Janssen. Thomas Bieber was speaker or consultant or Investigator for AbbVie, Affibody, Allmiral, AnaptysBio, Arena, Asana Biosciences, ASLAN pharma, Bayer Health, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Dermavant, Domain Therapeutics, EQRx, Eli Lilly and Company, Galderma, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, L'Oréal, MSD, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, UCB. He is founder and chairman of the board of the non-profit biotech “Davos Biosciences”. Sofia Ramiro research grants and/or consultancy fees: AbbVie, Eli Lilly, Janseen, Galapagos, MSD, Novartis, Pfizer, UCB, Sanofi. Subrata Ghosh declares receiving consulting fees from Pfizer, Janssen, AbbVie, Takeda, Bristol Myers Squibb, Receptos, Celgene, Gilead, Eli Lilly, and Boehringer Ingelheim, and speaker fees from AbbVie, Janssen, Takeda, Ferring, Pfizer, Shield, and Falk Pharma outside of the submitted work. Maria Antonietta D'Agostino reports speaker or consultant fees from Novartis, BMS, Janssen,Pfizer, Amgen, Galapagos, AbbVie, UCB, and Eli Lilly. PC reports research grants from UCB, MSD and Pfizer; speaker fees or consultant fees from Pfizer, MSD, Novartis, Bristol Myers Squibb, AbbVie, UCB, Eli Lilly, Gilead and Celgene Corporation. Britta Siegmund has served as consultant for Abbvie, Abivax, Arena, BMS, Boehringer, CED Service GmbH, Celgene, CT Scout, Endpoint Health, Falk, Forga Software, Galapagos, Janssen, Lilly, Materia Prima, Pfizer, Takeda, Pharma Insight, Predictimmune, PsiCro; Speaker fees: AbbVie, BMS, CED Service GmbH, Chiesi, Falk, Ferring, Gilead, Janssen, Lilly, Materia Prima, Takeda, Pfizer and grant support by Arena/Pfizer (served as representative of the Charité). Isabelle Chary-Valckenaere received consulting fees from Abbvie, BMS, Galapagos, Lilly, Novartis, Pfizer, UCB. Ailsa Hart has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Galapogos, Lilly, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Global Steering Committee for Genentech. Lorenzo Dagna Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Galapagos, GlaxoSmithKline, Janssen, Kiniksa Pharmaceuticals, Novartis, Pfizer, Sanofi-Genzyme, SOBI, and Vifor outside of the current work. Fernando Magro has served as a speaker and received honoraria from Merck Sharp & Dohme, Abbvie, Vifor, Falk, Laboratorios Vitoria, Ferring, Hospira, and Biogen. Renaud Felten has been a consultant for Amgen, BMS, Galapagos, GSK, Janssen-Cilag, Lilly, Medac, MSD, Nordic, Novartis, Pfizer, Sanofi, UCB. Paulo Kotze has received honoraria from AbbVie, Ferring, Janssen, Pfizer, and Takeda as a speaker and member of advisory boards. He also received scientific research grants from Pfizer and Takeda. Vipul Jairath has received consultancy/advisory board fees from AbbVie, Alimentiv Inc., Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker's fees from, Abbvie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda, and Fresenius Kabi. Antonio Costanzo has served as an advisory board member, consultant and has received fees and speaker's honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme and UCB-Pharma. Lars Erik Kristensen has received fees for participation in speakers bureaus, research grants and consultancy fees from Pfizer, AbbVie, Amgen, Galapagos, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly and Janssen Pharmaceuticals. Laurent Peyrin Biroulet has served as a speaker, consultant, and advisory board member for Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger Ingelheim, Lilly, HAC Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, and Theravance. Silvio Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma, and Vifor., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
22. Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease.
- Author
-
Schneider I, Allner C, Mühl L, Melde M, Lissner D, Mantzivi E, Glauben R, Vitali F, Becker E, Atreya I, Müller TM, Atreya R, Siegmund B, Neurath MF, and Zundler S
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Integrins metabolism, Gastrointestinal Agents therapeutic use, Inflammatory Bowel Diseases drug therapy
- Abstract
Inflammatory bowel diseases are medically intractable and require constant therapy in many cases. While a growing number of biologicals and small molecules is available for treatment, a substantial portion of patients experiences primary non-response to these compounds and head-to-head evidence for therapy selection is scarce. Thus, approaches to predict treatment success in individual patients are a huge unmet need. We had previously suggested that the expression and function of α4β7 integrin on T cells in the peripheral blood correlate to outcomes of therapy with the anti-α4β7 integrin antibody vedolizumab. Here, we conducted a translational multicenter trial to prospectively evaluate this hypothesis. In a cohort of 89 patients with inflammatory bowel disease undergoing regular therapy with vedolizumab, lower baseline expression of α4β7 was associated with short-term clinical response. Consistently, low α4β7 expression in patients achieving remission predicted sustained remission in week 30. Moreover, high dynamic adhesion of CD4
+ T cells to MAdCAM-1 and high reduction of adhesion by vedolizumab in vitro at baseline were associated with clinical remission. These data substantiate the potential of α4β7 integrin function and expression to forecast outcomes of vedolizumab therapy. Further translational efforts are necessary to improve the performance of the assays and to implement the concept in clinical practice., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
23. The combination of clinical parameters and immunophenotyping of intraepithelial lymphocytes allows to assess disease severity in refractory celiac disease.
- Author
-
Branchi F, Wiese JJ, Heldt C, Manna S, Dony V, Loddenkemper C, Bojarski C, Siegmund B, Schneider T, Daum S, Hummel M, Moos V, and Schumann M
- Subjects
- Humans, Immunophenotyping, Intestinal Mucosa pathology, Severity of Illness Index, Lymphocytes pathology, Celiac Disease complications, Intraepithelial Lymphocytes pathology
- Abstract
Background: Flow cytometry of intestinal lymphocytes is discussed to be a stronger predictor of enteropathy-associated T-cell lymphoma development in refractory celiac disease than T-cell clonality analysis., Aims: To investigate possible associations between clinical characteristics of refractory celiac disease patients and aberrant intraepithelial lymphocytes and to evaluate the accuracy of immunophenotyping for the identification of high-risk refractory celiac disease., Methods: Flow cytometry of isolated lymphocytes from duodenal biopsies of controls and celiac disease patients was performed and results were compared to clinical data., Results: Flow cytometry analysis was performed on 42 controls, 37 non-complicated celiac disease and 30 refractory celiac disease cases with or without T-cell receptor clonality. Elevated aberrant intraepithelial lymphocyte counts were significantly associated with severe malabsorption. A 15% cut-off (aberrant lymphocytes among all lymphocytes) had the best discriminatory ability to identify high-risk patients. However, this technique failed to identify some high-risk cases (sensitivity 63%, specificity 100%). The severity of malabsorption was added to the criteria for high-risk refractory celiac disease, improving the correct patients' allocation (sensitivity 100%, specificity 96%)., Conclusion: Immunophenotyping of aberrant intraepithelial lymphocytes is a good predictor for high-risk refractory celiac disease. Furthermore, adding the evaluation of malabsorption to the diagnostic assessment of refractory celiac disease optimizes accuracy., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
24. TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability.
- Author
-
Ninnemann J, Winsauer C, Bondareva M, Kühl AA, Lozza L, Durek P, Lissner D, Siegmund B, Kaufmann SHE, Mashreghi MF, Nedospasov SA, and Kruglov AA
- Subjects
- Biological Availability, Colon pathology, Humans, Inflammation metabolism, Interleukins, Intestinal Mucosa metabolism, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha metabolism, Interleukin-22, Colitis metabolism, Inflammatory Bowel Diseases metabolism
- Abstract
Successful treatment of chronic inflammatory diseases integrates both the cessation of inflammation and the induction of adequate tissue repair processes. Strikingly, targeting a single proinflammatory cytokine, tumor necrosis factor (TNF), induces both processes in a relevant cohort of inflammatory bowel disease (IBD) patients. However, the molecular mechanisms underlying intestinal repair following TNF blockade during IBD remain elusive. Using a novel humanized model of experimental colitis, we demonstrate that TNF interfered with the tissue repair program via induction of a soluble natural antagonist of IL-22 (IL-22Ra2; IL-22BP) in the colon and abrogated IL-22/STAT3-mediated mucosal repair during colitis. Furthermore, membrane-bound TNF expressed by T cells perpetuated colonic inflammation, while soluble TNF produced by epithelial cells (IECs) induced IL-22BP expression in colonic dendritic cells (DCs) and dampened IL-22-driven restitution of colonic epithelial functions. Finally, TNF induced IL-22BP expression in human monocyte-derived DCs and levels of IL22-BP correlated with TNF in sera of IBD patients. Thus, our data can explain how anti-TNF therapy induces mucosal healing by increasing IL-22 availability and implicates new therapeutic opportunities for IBD., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
25. A Notch/STAT3-driven Blimp-1/c-Maf-dependent molecular switch induces IL-10 expression in human CD4 + T cells and is defective in Crohn´s disease patients.
- Author
-
Ahlers J, Mantei A, Lozza L, Stäber M, Heinrich F, Bacher P, Hohnstein T, Menzel L, Yüz SG, Alvarez-Simon D, Bickenbach AR, Weidinger C, Mockel-Tenbrinck N, Kühl AA, Siegmund B, Maul J, Neumann C, and Scheffold A
- Subjects
- Animals, Humans, Interleukin-10 metabolism, Mice, Mice, Knockout, Proto-Oncogene Proteins c-maf genetics, Proto-Oncogene Proteins c-maf metabolism, STAT3 Transcription Factor metabolism, Th1 Cells metabolism, Crohn Disease metabolism, Inflammatory Bowel Diseases metabolism
- Abstract
Immunosuppressive Interleukin (IL)-10 production by pro-inflammatory CD4
+ T cells is a central self-regulatory function to limit aberrant inflammation. Still, the molecular mediators controlling IL-10 expression in human CD4+ T cells are largely undefined. Here, we identify a Notch/STAT3 signaling-module as a universal molecular switch to induce IL-10 expression across human naïve and major effector CD4+ T cell subsets. IL-10 induction was transient, jointly controlled by the transcription factors Blimp-1/c-Maf and accompanied by upregulation of several co-inhibitory receptors, including LAG-3, CD49b, PD-1, TIM-3 and TIGIT. Consistent with a protective role of IL-10 in inflammatory bowel diseases (IBD), effector CD4+ T cells from Crohn's disease patients were defective in Notch/STAT3-induced IL-10 production and skewed towards an inflammatory Th1/17 cell phenotype. Collectively, our data identify a Notch/STAT3-Blimp-1/c-Maf axis as a common anti-inflammatory pathway in human CD4+ T cells, which is defective in IBD and thus may represent an attractive therapeutic target., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
26. Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8 + T cells.
- Author
-
Lehmann M, Allers K, Heldt C, Meinhardt J, Schmidt F, Rodriguez-Sillke Y, Kunkel D, Schumann M, Böttcher C, Stahl-Hennig C, Elezkurtaj S, Bojarski C, Radbruch H, Corman VM, Schneider T, Loddenkemper C, Moos V, Weidinger C, Kühl AA, and Siegmund B
- Subjects
- Adult, Aged, Animals, Apoptosis, CD8-Positive T-Lymphocytes virology, COVID-19 pathology, COVID-19 virology, Case-Control Studies, Cell Proliferation, Chlorocebus aethiops, Duodenum pathology, Duodenum virology, Female, Host-Pathogen Interactions, Humans, Intestinal Diseases pathology, Intestinal Diseases virology, Intestinal Mucosa pathology, Intestinal Mucosa virology, Intraepithelial Lymphocytes virology, Male, Re-Epithelialization, SARS-CoV-2 pathogenicity, Vero Cells, Viral Load, CD8-Positive T-Lymphocytes immunology, COVID-19 immunology, Duodenum immunology, Immunity, Mucosal, Intestinal Diseases immunology, Intestinal Mucosa immunology, Intraepithelial Lymphocytes immunology, Lymphocyte Activation, SARS-CoV-2 immunology
- Abstract
The SARS-CoV-2 pandemic has so far claimed over three and a half million lives worldwide. Though the SARS-CoV-2 mediated disease COVID-19 has first been characterized by an infection of the upper airways and the lung, recent evidence suggests a complex disease including gastrointestinal symptoms. Even if a direct viral tropism of intestinal cells has recently been demonstrated, it remains unclear, whether gastrointestinal symptoms are caused by direct infection of the gastrointestinal tract by SARS-CoV-2 or whether they are a consequence of a systemic immune activation and subsequent modulation of the mucosal immune system. To better understand the cause of intestinal symptoms we analyzed biopsies of the small intestine from SARS-CoV-2 infected individuals. Applying qRT-PCR and immunohistochemistry, we detected SARS-CoV-2 RNA and nucleocapsid protein in duodenal mucosa. In addition, applying imaging mass cytometry and immunohistochemistry, we identified histomorphological changes of the epithelium, which were characterized by an accumulation of activated intraepithelial CD8
+ T cells as well as epithelial apoptosis and subsequent regenerative proliferation in the small intestine of COVID-19 patients. In summary, our findings indicate that intraepithelial CD8+ T cells are activated upon infection of intestinal epithelial cells with SARS-CoV-2, providing one possible explanation for gastrointestinal symptoms associated with COVID-19., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
27. Influence of fibrosis progression on the viscous properties of in vivo liver tissue elucidated by shear wave dispersion in multifrequency MR elastography.
- Author
-
Reiter R, Shahryari M, Tzschätzsch H, Haas M, Bayerl C, Siegmund B, Hamm B, Asbach P, Braun J, and Sack I
- Subjects
- Biopsy, Humans, Liver diagnostic imaging, Liver Cirrhosis diagnostic imaging, Viscosity, Elasticity Imaging Techniques
- Abstract
Purpose: Many elastography studies have shown that liver stiffness increases with fibrosis and thus can be used as a reliable marker for noninvasively staging fibrosis. However, the sensitivity of viscosity-related mechanical parameters, such as shear wave dispersion, to liver fibrosis is less well understood., Methods: In this proof-of-concept study, 15 healthy volunteers and 37 patients with chronic liver disease and biopsy-proven fibrosis were prospectively investigated by MR elastography at six drive frequencies of 35-60 Hz. Maps of shear wave speed (SWS, in m/s) and loss angle (φ, in rad), as a marker of stiffness and viscous properties, respectively, were generated using tomoelastography data processing. The Child-Pugh score was used to assess cirrhosis severity., Results: While SWS increased with fibrosis (F0: 1.53 ± 0.11 m/s, F1-F3: 1.71 ± 0.17 m/s, F4: 2.50 ± 0.39 m/s; P < 0.001), φ remained unchanged during mild to severe fibrosis (F0: 0.63 ± 0.05 rad, F1-F3: 0.60 ± 0.05 rad, P = 0.21) but increased in cirrhosis (F4: 0.81 ± 0.16 rad; P < 0.001). Correspondingly, the slope of SWS-dispersion within the investigated range of vibration frequencies increased from insignificant (F0-F3: 0.010 ± 0.007 m/s/Hz) to significant (F4: 0.038 ± 0.025 m/s/Hz; P = 0.005). Significant correlation with the Child-Pugh score was found for φ (R = 0.60, P = 0.01) but not for SWS., Conclusion: Although cirrhosis is associated with liver stiffening and, intuitively, transition towards more rigid material properties, the observed increases in φ and slope of SWS-dispersion indicate abnormally high mechanical friction in cirrhotic livers. This biophysical signature might provide a prognostic imaging marker for the detection of pathological processes associated with fibrosis independent of stiffness., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
28. COVID-19-from mucosal immunology to IBD patients.
- Author
-
Weidinger C, Hegazy AN, Glauben R, and Siegmund B
- Subjects
- Biomarkers, COVID-19 diagnosis, COVID-19 virology, Humans, Immunity, Innate, Inflammatory Bowel Diseases diagnosis, Intestinal Mucosa immunology, Intestinal Mucosa metabolism, Intestinal Mucosa pathology, Severity of Illness Index, Symptom Assessment, Viral Tropism, Virus Internalization, COVID-19 complications, COVID-19 immunology, Host-Pathogen Interactions immunology, Immunity, Mucosal, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases immunology, SARS-CoV-2 physiology
- Abstract
Viral infections with SARS-CoV-2 can cause a multi-facetted disease, which is not only characterized by pneumonia and overwhelming systemic inflammatory immune responses, but which can also directly affect the digestive system and infect intestinal epithelial cells. Here, we review the current understanding of intestinal tropism of SARS-CoV-2 infection, its impact on mucosal function and immunology and summarize the effect of immune-suppression in patients with inflammatory bowel disease (IBD) on disease outcome of COVID-19 and discuss IBD-relevant implications for the clinical management of SARS-CoV-2 infected individuals.
- Published
- 2021
- Full Text
- View/download PDF
29. Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19.
- Author
-
Hardenberg JB, Stockmann H, Aigner A, Gotthardt I, Enghard P, Hinze C, Balzer F, Schmidt D, Zickler D, Kruse J, Körner R, Stegemann M, Schneider T, Schumann M, Müller-Redetzky H, Angermair S, Budde K, Weber-Carstens S, Witzenrath M, Treskatsch S, Siegmund B, Spies C, Suttorp N, Rauch G, Eckardt KU, and Schmidt-Ott KM
- Abstract
Introduction: Acute kidney injury (AKI) is an important complication in COVID-19, but its precise etiology has not fully been elucidated. Insights into AKI mechanisms may be provided by analyzing the temporal associations of clinical parameters reflecting disease processes and AKI development., Methods: We performed an observational cohort study of 223 consecutive COVID-19 patients treated at 3 sites of a tertiary care referral center to describe the evolvement of severe AKI (Kidney Disease: Improving Global Outcomes stage 3) and identify conditions promoting its development. Descriptive statistics and explanatory multivariable Cox regression modeling with clinical parameters as time-varying covariates were used to identify risk factors of severe AKI., Results: Severe AKI developed in 70 of 223 patients (31%) with COVID-19, of which 95.7% required kidney replacement therapy. Patients with severe AKI were older, predominantly male, had more comorbidities, and displayed excess mortality. Severe AKI occurred exclusively in intensive care unit patients, and 97.3% of the patients developing severe AKI had respiratory failure. Mechanical ventilation, vasopressor therapy, and inflammatory markers (serum procalcitonin levels and leucocyte count) were independent time-varying risk factors of severe AKI. Increasing inflammatory markers displayed a close temporal association with the development of severe AKI. Sensitivity analysis on risk factors of AKI stage 2 and 3 combined confirmed these findings., Conclusion: Severe AKI in COVID-19 was tightly coupled with critical illness and systemic inflammation and was not observed in milder disease courses. These findings suggest that traditional systemic AKI mechanisms rather than kidney-specific processes contribute to severe AKI in COVID-19., (© 2021 International Society of Nephrology. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
30. Transcranial direct current stimulation in inflammatory bowel disease patients modifies resting-state functional connectivity: A RCT.
- Author
-
Neeb L, Bayer A, Bayer KE, Farmer A, Fiebach JB, Siegmund B, and Volz MS
- Subjects
- Adult, Brain physiology, Double-Blind Method, Female, Humans, Male, Middle Aged, Nerve Net physiology, Rest physiology, Brain diagnostic imaging, Inflammatory Bowel Diseases diagnostic imaging, Inflammatory Bowel Diseases therapy, Magnetic Resonance Imaging methods, Nerve Net diagnostic imaging, Transcranial Direct Current Stimulation methods
- Abstract
Background: Chronic pain is known to be associated with functional and structural changes in the brain. Inflammatory bowel disease (IBD) presents with chronic abdominal pain in almost 35% of all patients. This study investigates structural and functional changes in magnetic resonance imaging (MRI) after transcranial direct current stimulation (tDCS) applied to ameliorate pain in IBD., Methods: This phase-III, placebo-controlled, randomized study included 36 patients with IBD and chronic pain. MRI scans were performed before and following tDCS, which was applied for 5 days., Results/conclusion: For the first time, this study revealed an association of changes in resting-state functional MRI and pain reduction in IBD. There was a significant increase in functional connectivity after active tDCS within the visual medial and the right frontoparietal network being connected with the amygdala, the insula, and the primary somatosensory cortex indicating central pain mechanisms in IBD. Moreover, tDCS offers a novel therapeutic strategy for abdominal pain., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
31. HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFβ1 signalling in inflammation.
- Author
-
Friedrich M, Gerbeth L, Gerling M, Rosenthal R, Steiger K, Weidinger C, Keye J, Wu H, Schmidt F, Weichert W, Siegmund B, and Glauben R
- Subjects
- Animals, Autocrine Communication, Cells, Cultured, Colitis chemically induced, Disease Models, Animal, Electric Impedance, Humans, Mice, Mice, Inbred C57BL, Regeneration, Signal Transduction, Tight Junctions physiology, Transforming Growth Factor beta1 metabolism, Wound Healing, Carbamates therapeutic use, Colitis drug therapy, Epithelial Cells physiology, Histone Deacetylase Inhibitors therapeutic use, Inflammatory Bowel Diseases drug therapy, Intestines physiology, Tight Junctions drug effects, Vorinostat therapeutic use
- Abstract
Intact epithelial barrier function is pivotal for maintaining intestinal homeostasis. Current therapeutic developments aim at restoring the epithelial barrier in inflammatory bowel disease. Histone deacetylase (HDAC) inhibitors are known to modulate immune responses and to ameliorate experimental colitis. However, their direct impact on epithelial barrier function and intestinal wound healing is unknown. In human and murine colonic epithelial cell lines, the presence of the HDAC inhibitors Givinostat and Vorinostat not only improved transepithelial electrical resistance under inflammatory conditions but also attenuated the passage of macromolecules across the epithelial monolayer. Givinostat treatment mediated an accelerated wound closure in scratch assays. In vivo, Givinostat treatment resulted in improved barrier recovery and epithelial wound healing in dextran sodium sulphate-stressed mice. Mechanistically, these regenerative effects could be linked to an increased secretion of transforming growth factor beta1 and interleukin 8, paralleled by differential expression of the tight junction proteins claudin-1, claudin-2 and occludin. Our data reveal a novel tissue regenerative property of the pan-HDAC inhibitors Givinostat and Vorinostat in intestinal inflammation, which may have beneficial implications by repurposing HDAC inhibitors for therapeutic strategies for inflammatory bowel disease.
- Published
- 2019
- Full Text
- View/download PDF
32. Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon.
- Author
-
Bücker R, Krug SM, Moos V, Bojarski C, Schweiger MR, Kerick M, Fromm A, Janßen S, Fromm M, Hering NA, Siegmund B, Schneider T, Barmeyer C, and Schulzke JD
- Subjects
- Adult, Apoptosis, Cells, Cultured, Colon microbiology, Computational Biology, Cytokines genetics, Cytokines metabolism, Enteritis microbiology, Epithelial Sodium Channels metabolism, Female, Humans, Inflammation Mediators metabolism, Intestinal Mucosa pathology, Ion Transport, Malabsorption Syndromes microbiology, Male, Middle Aged, Signal Transduction, Tight Junction Proteins metabolism, Vitamin D metabolism, Campylobacter Infections immunology, Campylobacter jejuni physiology, Colon immunology, Enteritis immunology, Intestinal Mucosa metabolism, Malabsorption Syndromes immunology, Sodium metabolism
- Abstract
Campylobacter jejuni is the most prevalent cause of foodborne bacterial enteritis worldwide. Patients present with diarrhea and immune responses lead to complications like arthritis and irritable bowel syndrome. Although studies exist in animal and cell models, we aimed at a functional and structural characterization of intestinal dysfunction and the involved regulatory mechanisms in human colon. First, in patients' colonic biopsies, sodium malabsorption was identified as an important diarrheal mechanism resulting from hampered epithelial ion transport via impaired epithelial sodium channel (ENaC) β- and γ-subunit. In addition, barrier dysfunction from disrupted epithelial tight junction proteins (claudin-1, -3, -4, -5, and -8), epithelial apoptosis, and appearance of lesions was detected, which cause leak-flux diarrhea and can perpetuate immune responses. Importantly, these effects in human biopsies either represent direct action of Campylobacter jejuni (ENaC impairment) or are caused by proinflammatory signaling (barrier dysfunction). This was revealed by regulator analysis from RNA-sequencing (cytometric bead array-checked) and confirmed in cell models, which identified interferon-γ, TNFα, IL-13, and IL-1β. Finally, bioinformatics' predictions yielded additional information on protective influences like vitamin D, which was confirmed in cell models. Thus, these are candidates for intervention strategies against C. jejuni infection and post-infectious sequelae, which result from the permissive barrier defect along the leaky gut.
- Published
- 2018
- Full Text
- View/download PDF
33. Architectural and functional alterations of the small intestinal mucosa in classical Whipple's disease.
- Author
-
Epple HJ, Friebel J, Moos V, Troeger H, Krug SM, Allers K, Schinnerling K, Fromm A, Siegmund B, Fromm M, Schulzke JD, and Schneider T
- Subjects
- Adult, Aged, Apoptosis, Atrophy, Claudins metabolism, Female, Humans, Hyperplasia, Immunity, Mucosal, Interleukin-13 metabolism, MARVEL Domain Containing 2 Protein metabolism, Male, Middle Aged, Tight Junctions, Tumor Necrosis Factor-alpha metabolism, Young Adult, Duodenum pathology, Intestinal Mucosa immunology, Intestine, Small pathology, Whipple Disease immunology
- Abstract
Classical Whipple's disease (CWD) affects the gastrointestinal tract and rather elicits regulatory than inflammatory immune reactions. Mechanisms of malabsorption, diarrhea, and systemic immune activation are unknown. We here analyzed mucosal architecture, barrier function, and immune activation as potential diarrheal trigger in specimens from 52 CWD patients. Our data demonstrate villus atrophy and crypt hyperplasia associated with epithelial apoptosis and reduced alkaline phosphatase expression in the duodenum of CWD patients. Electrophysiological and flux experiments revealed increased duodenal permeability to small solutes and macromolecules. Duodenal architecture and permeability ameliorated upon antibiotic treatment. Structural correlates for these alterations were concordant changes of membranous claudin-1, claudin-2, claudin-3, and tricellulin expression. Tumor necrosis factor-α and interleukin-13 were identified as probable mediators of epithelial apoptosis, and altered tight junction expression. Increased serum markers of microbial translocation and their decline following treatment corroborated the biological significance of the mucosal barrier defect. Hence, mucosal immune responses in CWD elicit barrier dysfunction. Diarrhea is caused by loss of absorptive capacity and leak flux of ions and water. Downregulation of tricellulin causes increased permeability to macromolecules and subsequent microbial translocation contributes to systemic inflammation. Thus, therapeutic strategies to reconstitute the mucosal barrier and control inflammation could assist symptomatic control of CWD.
- Published
- 2017
- Full Text
- View/download PDF
34. Inflammatory cell infiltration and resolution of kidney inflammation is orchestrated by the cold-shock protein Y-box binding protein-1.
- Author
-
Bernhardt A, Fehr A, Brandt S, Jerchel S, Ballhause TM, Philipsen L, Stolze S, Geffers R, Weng H, Fischer KD, Isermann B, Brunner-Weinzierl MC, Batra A, Siegmund B, Zhu C, Lindquist JA, and Mertens PR
- Subjects
- Animals, Cell Communication, Chemokine CCL5 metabolism, Coculture Techniques, DNA-Binding Proteins genetics, Disease Models, Animal, Disease Progression, Female, Fibrosis, Humans, Interleukin-10 metabolism, Kidney Tubules cytology, Macrophages, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Monocytes metabolism, Myofibroblasts metabolism, Myofibroblasts pathology, Primary Cell Culture, Cell Differentiation, DNA-Binding Proteins metabolism, Kidney Tubules pathology, Monocytes pathology, Nephritis, Interstitial pathology
- Abstract
Tubular cells recruit monocytic cells in inflammatory tubulointerstitial kidney diseases. The cell-cell communication that establishes pro- or anti-inflammatory activities is mainly influenced by cytokines, reactive oxygen species, nitric oxide, and phagocytosis. Key proteins orchestrating these processes such as cold-shock proteins linked with chemoattraction and cell maturation have been identified. The prototypic member of the cold-shock protein family, Y-box binding protein (YB)-1, governs specific phenotypic alterations in monocytic cells and was explored in the present study. Following tubulointerstitial injury by unilateral ureteral obstruction, increased inflammatory cell infiltration and tubular cell CCL5 expression was found in conditional Ybx1 knockout animals with specific depletion in monocytes/macrophages (YB-1
ΔLysM ). Furthermore, YB-1ΔLysM mice exhibit enhanced tissue damage, myofibroblast activation, and fibrosis. To investigate relevant molecular mechanism(s), we utilized bone marrow-derived macrophage cultures and found that YB-1-deficient macrophages display defects in cell polarization and function, including reduced proliferation and nitric oxide production, loss of phagocytic activity, and failure to upregulate IL-10 and CCL5 expression in response to inflammatory stimuli. Co-culture with primary tubular cells confirmed these findings. Thus, monocytic YB-1 has prominent and distinct roles for cellular feed-forward crosstalk and resolution of inflammatory processes by its ability to regulate cell differentiation and cytokine/chemokine synthesis., (Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
35. Is intensity the solution for FMT in ulcerative colitis?
- Author
-
Siegmund B
- Subjects
- Humans, Microbiota, Colitis, Ulcerative, Feces
- Published
- 2017
- Full Text
- View/download PDF
36. Inhibitor development and mortality in non-severe hemophilia A.
- Author
-
Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, and Fijnvandraat K
- Subjects
- Adolescent, Adult, Aged, Australia, Biomarkers blood, Cause of Death, Child, Europe, Hemophilia A blood, Hemophilia A diagnosis, Hemorrhage blood, Hemorrhage diagnosis, Humans, Male, Middle Aged, Retrospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Young Adult, Antibodies, Neutralizing blood, Autoantibodies blood, Factor VIII immunology, Hemophilia A immunology, Hemophilia A mortality, Hemorrhage immunology, Hemorrhage mortality
- Abstract
Background: The life expectancy of non-severe hemophilia A (HA) patients equals the life expectancy of the non-hemophilic population. However, data on the effect of inhibitor development on mortality and on hemophilia-related causes of death are scarce. The development of neutralizing factor VIII antibodies in non-severe HA patients may dramatically change their clinical outcome due to severe bleeding complications., Objectives: We assessed the association between the occurrence of inhibitors and mortality in patients with non-severe HA., Methods: In this retrospective cohort study, clinical data and vital status were collected for 2709 non-severe HA patients (107 with inhibitors) who were treated between 1980 and 2011 in 34 European and Australian centers. Mortality rates for patients with and without inhibitors were compared., Results: During 64,200 patient-years of follow-up, 148 patients died (mortality rate, 2.30 per 1000 person-years; 95% confidence interval (CI), 1.96-2.70) at a median age of 64 years (interquartile range [IQR], 49-76). In 62 patients (42%) the cause of death was hemophilia related. Sixteen inhibitor patients died at a median age of 71 years (IQR, 60-81). In ten patients the inhibitor was present at time of death; seven of them died of severe bleeding complications. The all-cause mortality rate in inhibitor patients was > 5 times increased compared with that for those without inhibitors (age-adjusted mortality rate ratio, 5.6)., Conclusion: Inhibitor development in non-severe hemophilia is associated with increased mortality. High rates of hemophilia-related mortality in this study indicate that non-severe hemophilia is not mild at all and stress the importance of close follow-up for these patients., (© 2015 International Society on Thrombosis and Haemostasis.)
- Published
- 2015
- Full Text
- View/download PDF
37. Intermittent dyspnea and cyanosis in a newborn caused by a hairy polyp.
- Author
-
Lignitz S, Haug V, Siegmund B, Mann WJ, Coerdt W, and Mildenberger E
- Subjects
- Gestational Age, Humans, Infant, Newborn, Male, Nasopharyngeal Diseases pathology, Nasopharyngeal Diseases surgery, Polyps pathology, Polyps surgery, Cyanosis etiology, Dyspnea etiology, Nasopharyngeal Diseases complications, Polyps complications
- Published
- 2014
- Full Text
- View/download PDF
38. Exploring & exploiting our 'other self' - does the microbiota hold the key to the future therapy in Crohn's?
- Author
-
Haag LM and Siegmund B
- Subjects
- Humans, Intestinal Mucosa microbiology, Crohn Disease microbiology, Crohn Disease therapy, Microbiota, Probiotics therapeutic use
- Abstract
Inflammatory bowel diseases (IBD) with its two major forms Crohn's disease (CD) and ulcerative colitis (UC) are chronic relapsing disorders leading to inflammation of the gastrointestinal tract. Although the precise aetiology of IBD remains unclear, several factors are believed to contribute to disease pathogenesis. Among these, the role of the intestinal microbiota has become more and more appreciated. Evidence from experimental and clinical studies strongly suggests that chronic intestinal inflammation results from a dysregulated immune response towards components of the microbiota in genetically susceptible hosts. The growing perception of the microbiota as a major driver of disease pathogenesis raises the question, if the intestinal microbiota can be used as a therapeutic target in CD. Based on what we know about host microbiota interactions in health and disease, the objective of this review is to address the question if the microbiota holds the key to the future therapy in CD., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
39. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
- Author
-
Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, and Fijnvandraat K
- Subjects
- Adolescent, Adult, Factor VIII therapeutic use, Follow-Up Studies, Genotype, Hemophilia A drug therapy, Humans, Kaplan-Meier Estimate, Middle Aged, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Antibodies, Neutralizing immunology, Factor VIII genetics, Factor VIII immunology, Hemophilia A genetics, Hemophilia A immunology, Mutation, Missense
- Abstract
Neutralizing antibodies (inhibitors) toward factor VIII form a severe complication in nonsevere hemophilia A, profoundly aggravating the bleeding pattern. Identification of high-risk patients is hampered by lack of data that take exposure days to therapeutic factor VIII concentrates into account. In the INSIGHT study, we analyzed the association between F8 mutation and inhibitor development in patients with nonsevere hemophilia A (factor VIII 2-40 IU/dL). This analysis included 1112 nonsevere hemophilia A patients from 14 centers in Europe and Australia that had genotyped at least 70% of their patients. Inhibitor risk was calculated as Kaplan-Meier incidence with cumulative number of exposure days as the time variable. During 44 800 exposure days (median, 24 exposure days per patient; interquartile range [IQR], 7-90), 59 of the 1112 patients developed an inhibitor; cumulative incidence of 5.3% (95% confidence interval [CI], 4.0-6.6) after a median of 28 exposure days (IQR, 12-71). The inhibitor risk at 50 exposure days was 6.7% (95% CI, 4.5-8.9) and at 100 exposure days the risk further increased to 13.3% (95% CI, 9.6-17.0). Among a total of 214 different F8 missense mutations 19 were associated with inhibitor development. These results emphasize the importance of F8 genotyping in nonsevere hemophilia A.
- Published
- 2013
- Full Text
- View/download PDF
40. Mesenteric fat - control site for bacterial translocation in colitis?
- Author
-
Batra A, Heimesaat MM, Bereswill S, Fischer A, Glauben R, Kunkel D, Scheffold A, Erben U, Kühl A, Loddenkemper C, Lehr HA, Schumann M, Schulzke JD, Zeitz M, and Siegmund B
- Subjects
- Adipocytes immunology, Animals, Cell Movement, Cells, Cultured, Colitis chemically induced, Colitis microbiology, Crohn Disease microbiology, Dextran Sulfate administration & dosage, Disease Models, Animal, Female, Humans, Mesentery pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, Myeloid Differentiation Factor 88 genetics, Myeloid Differentiation Factor 88 metabolism, Peptide Fragments administration & dosage, Phagocytosis, B-Lymphocytes immunology, Bacterial Translocation, Colitis immunology, Crohn Disease immunology, Intra-Abdominal Fat immunology, T-Lymphocytes immunology
- Abstract
In Crohn's disease bacteria could be detected in the adjacent mesenteric fat characterized by hypertrophy of unknown function. This study aimed to define effector responses of this compartment induced by bacterial translocation during intestinal inflammation. Dextran sulfate sodium-induced colitis served as a model of intestinal inflammation. Translocation of peptides and bacteria into mesenteric fat was evaluated. Innate functions of mesenteric fat and epithelium were characterized at whole tissue, cellular, and effector molecule levels. Orally applied peptides translocated in healthy wild-type (WT) mice. Bacterial translocation was not detected in healthy and acute but increased in chronic colitis. Mesenteric fat from colitic mice released elevated levels of cytokines and was infiltrated by immune cells. In MyD88(-/-) mice bacterial translocation occurred in health and increased in colitis. The exaggerated cytokine production in mesenteric fat accompanying colonic inflammation in WT mice was less distinct in MyD88(-/-) mice. In vitro studies revealed that fat not only increases cytokine production following contact with bacterial products, but also that preadipocytes are potent phagocytes. Colonic inflammation is accompanied by massive cytokine production and immune cell infiltration in adjacent adipose tissue. These effects can be considered as protective mechanisms of the mesenteric fat in the defense of bacterial translocation.
- Published
- 2012
- Full Text
- View/download PDF
41. CCR7 deficiency causes diarrhea associated with altered ion transport in colonocytes in the absence of overt colitis.
- Author
-
Schumann M, Winter S, Wichner K, May C, Kühl AA, Batra A, Siegmund B, Zeitz M, Schulzke JD, Lipp M, and Höpken UE
- Subjects
- Animals, Biomarkers, Chlorides metabolism, Colon immunology, Colon metabolism, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Epithelial Sodium Channels genetics, Epithelial Sodium Channels metabolism, Immunoglobulin G blood, Immunoglobulin G immunology, Immunoglobulin M blood, Immunoglobulin M immunology, Interleukin-1beta biosynthesis, Intestinal Mucosa, Lymphocyte Activation immunology, Mice, Mice, Inbred C57BL, Mice, Knockout, Peyer's Patches immunology, Peyer's Patches metabolism, RNA, Messenger metabolism, Receptors, CCR7 genetics, Rectal Prolapse genetics, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory metabolism, Colitis genetics, Colitis metabolism, Diarrhea genetics, Diarrhea metabolism, Ion Transport, Receptors, CCR7 deficiency
- Abstract
The chemokine receptor CCR7 is a central regulator in the maintenance of cellular homeostasis of mucosal tissues. CCR7⁻/⁻ mice develop autoimmune gastritis and exocrinopathy accompanied by the formation of mucosal tertiary lymphoid follicles. Here we found that CCR7-deficient mice frequently suffered from chronic diarrhea linked with increased gastrointestinal motility and the development of severe anorectal prolapse. Enhanced formation of intestinal lymphoid follicles was associated with an elevated proportion of activated colonic T cells and increased production of the cytokine interleukin (IL)-1β. To uncover the pathomechanisms of diarrhea in CCR7⁻/⁻ mice, colonic epithelial barrier and ion channel activities were analyzed in Ussing chambers. Although overt acute colitis was absent, CCR7 deficiency resulted in reduced electrogenic sodium absorption and colonic chloride secretion. As it is known that IL-1β regulates epithelial sodium channel (ENaC) activity, these data imply a causal link between CCR7 expression, IL-1β level, and Na⁺ malabsorption owing to altered ENaC expression and diarrhea.
- Published
- 2012
- Full Text
- View/download PDF
42. Manifestation of spontaneous and early autoimmune gastritis in CCR7-deficient mice.
- Author
-
Winter S, Rehm A, Wichner K, Scheel T, Batra A, Siegmund B, Berek C, Lipp M, and Höpken UE
- Subjects
- Animals, Bone Marrow Cells cytology, CD11c Antigen biosynthesis, CD4-Positive T-Lymphocytes cytology, Dendritic Cells cytology, Flow Cytometry methods, Gastric Mucosa metabolism, Hydrogen-Ion Concentration, Immunoglobulin G chemistry, Interferon-gamma metabolism, Interleukin-17 metabolism, Leukocytes, Mononuclear cytology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Autoimmune Diseases pathology, Gastritis pathology, Receptors, CCR7 genetics
- Abstract
Autoimmune gastritis is a common autoimmune disorder characterized by chronic inflammatory cell infiltrates, atrophy of the corpus and fundus, and the occurrence of autoantibodies to parietal cell antigen. In CCR7-deficient mice, autoimmune gastritis developed spontaneously and was accompanied by metaplasia of the gastric mucosa and by the formation of tertiary lymphoid organs at gastric mucosal sites. T cells of CCR7-deficient mice showed an activated phenotype in the gastric mucosa, mesenteric lymph nodes, and peripheral blood. In addition, elevated serum IgG levels specific to gastric parietal cell antigen were detected. Because the role of organized lymphocytic aggregates at this inflammatory site is not completely understood, we first analyzed the cellular requirements for the formation of these structures. Autoreactive CD4(+) T cells were pivotal for tertiary lymphoid follicle formation, most likely in cooperation with dendritic cells, macrophages, and B cells. Second, we analyzed the necessity of secondary lymph nodes and tertiary lymphoid organs for the development of autoimmune gastritis using CCR7 single- and CCR7/lymphotoxin α double-deficient mice. Strikingly, manifestation of autoimmune gastritis was observed in the absence of secondary lymph nodes and preceded the development of tertiary lymphoid organs. Taken together, these findings identify an inflammatory process where gastric autoreactive T cells independent of organized tertiary lymphoid organs and classic lymph nodes can induce and maintain autoimmune gastritis., (Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
43. Leptin-dependent toll-like receptor expression and responsiveness in preadipocytes and adipocytes.
- Author
-
Batra A, Pietsch J, Fedke I, Glauben R, Okur B, Stroh T, Zeitz M, and Siegmund B
- Subjects
- Adipocytes cytology, Androstadienes metabolism, Animals, Cells, Cultured, Female, Interleukin-6 metabolism, Lipopolysaccharides metabolism, Mice, Mice, Inbred C57BL, Mice, Obese, Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors, Protein Isoforms genetics, Protein Isoforms metabolism, Proto-Oncogene Proteins c-akt metabolism, Receptors, Leptin, Signal Transduction physiology, Stem Cells cytology, Toll-Like Receptors genetics, Wortmannin, Adipocytes metabolism, Leptin metabolism, Stem Cells metabolism, Toll-Like Receptors metabolism
- Abstract
Leptin, an adipokine mainly produced by adipocytes, has been well characterized with regard to its regulatory function on immune cells. Thus the question occurred of how adipocytes and preadipocytes interact with the immune system and whether or not this communication is regulated by leptin. With the present study we evaluated the Toll-like receptor (TLR) expression and TLR ligand-specific activation of murine preadipocytes and adipocytes in the presence [wild type (WT), 3T3L1] or absence of leptin (ob/ob) or leptin signaling (db/db). The ob/ob as well as db/db adipocytes and preadipocytes were characterized by a significant up-regulation of TLR1 to -9 expression when compared with WT cells. In WT preadipocytes the TLR responsiveness increased during maturation to adipocytes; however, stimulation of ob/ob and db/db cells resulted in a 10- to 20-fold higher interleukin-6 production. Signaling studies revealed, in addition to the increased TLR expression, alterations in the phosphoinositide 3 kinase signaling cascade in ob/ob and db/db cells as an explanation for this increased responsiveness. In conclusion, the present study indicates the expression and responsiveness of TLR1 to -9 in murine preadipocytes as well as adipocytes, both of which are strongly regulated by the adipokine leptin. In summary, these data further emphasize the role of fat tissue in the immune system.
- Published
- 2007
- Full Text
- View/download PDF
44. Development of a simple sample preparation technique for gas chromatographic-mass spectrometric determination of nicotine in edible nightshades (Solanaceae).
- Author
-
Siegmund B, Leitner E, and Pfannhauser W
- Subjects
- Air analysis, Calibration, Gas Chromatography-Mass Spectrometry, Solanum lycopersicum chemistry, Reference Standards, Reproducibility of Results, Solvents, Nicotine analysis, Solanaceae chemistry
- Abstract
The purpose of this study was to develop a rapid analytical method for the reliable determination of low concentrations of nicotine in foods for large numbers of samples. Food material was extracted using a simple liquid-liquid extraction method. For processed foods, further clean-up steps had to be employed to eliminate interfering compounds. The determination of nicotine was performed by gas chromatography-mass spectrometry. Quantitative analysis was accomplished using deuterium labeled nicotine as an internal standard. Recoveries of over 95% were obtained for a single step extraction, as well as for a multiple-stage extraction procedure, respectively. The method has been applied to the determination of nicotine in edible nightshades (i.e. tomatoes, potatoes and aubergines) and their processed products.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.